Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.

ABSTRACT:

Objectives

To assess real-world treatment patterns and healthcare resource utilization (HRU) among patients with FLT3-mutated (FLT3^mut ) and FLT3-wild-type (FLT3^wt ) acute myeloid leukemia (AML).

Methods

Data were abstracted from medical charts of patients with AML from 10 countries. Patients were grouped based on their FLT3 mutation status, age (18-64 or ?65), and whether they were newly diagnosed (ND) or relapsed/refractory (R/R).

Results

Charts of 1027 AML patients were included (183 FLT3^mut 18-64 ND; 136 FLT3^mut ?65 ND; 181 FLT3^mut R/R; 186 FLT3^wt 18-64 ND; 159 FLT3^wt ?65 ND; 182 FLT3^wt R/R). Substantial heterogeneity was observed in treatment patterns for AML. Among ND patients 18-64, the most common initial treatment was standard-to-intermediate dose cytarabine-based therapies (43.2% for FLT3^mut and 55.9% for FLT3^wt ); among ND patients ?65, the most common initial treatment was hypomethylating agent-based therapies (36.0% and 47.2%). Among R/R patients, the most common initial treatment after R/R was best supportive care only (39.8% and 24.7%). HRU was substantial across cohorts during both event-free and post-event periods.

Conclusions

Treatment patterns of AML were heterogeneous and FLT3^mut AML was treated more aggressively than FLT3^wt disease. HRU was substantial for all cohorts, particularly after relapse or treatment failure.

SUBMITTER: Griffin JD 

PROVIDER: S-EPMC6850763 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature